Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk

Kuchay, Mohammad Shafi; Martínez‐Montoro, José Ignacio; Kaur, Parjeet; Fernández‐García, José Carlos; Ramos‐Molina, Bruno

doi:10.1016/j.arr.2022.101696

Cited by 21 publications

(9 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAFLD and sarcopenia, which share various pathophysiologic mechanisms, have become increasingly prevalent conditions, resulting in a significant health burden [ 61 ]. Previous Asian studies determined sarcopenia is independently associated with NAFLD [ 62 , 63 ] and NAFLD-associated fibrosis [ 64 ].…”

Section: High-risk Profiles For Mortality In Nafldmentioning

confidence: 99%

See 1 more Smart Citation

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

2023

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extrahepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more longterm mortality data may demonstrate an independent association between NAFLD and mortality.

show abstract

Section: High-risk Profiles For Mortality In Nafldmentioning

confidence: 99%

“…Other research is consistent with this finding [ 67 , 68 ]. Both NAFLD and sarcopenia confer increased risk for adverse outcomes mediated by a combination of additive and synergic risk factors for all-cause and cardiovascular-related mortality [ 61 ].…”

Section: High-risk Profiles For Mortality In Nafldmentioning

confidence: 99%

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

2023

View full text Add to dashboard Cite

show abstract

“…As one of the energy metabolism organs, skeletal muscle can affect liver lipid and glucose metabolism by regulating systemic metabolic homeostasis. In addition, decreased skeletal muscle mass and altered myokine secretion are associated with exacerbation of NAFLD progression[ 129 , 130 ]. Myostatin signaling negatively regulates muscle mass and is positively related to liver fibrosis[ 131 ].…”

Section: Potential Targets Outside the Livermentioning

confidence: 99%

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

Wang¹,

Zhang²,

Guan³

2023

World J Gastroenterol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD), a leading chronic disease worldwide, affects approximately a quarter of the global population. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD and is more likely to progress to liver fibrosis than simple steatosis. NASH is also identified as the most rapidly growing cause of hepatocellular carcinoma. Although in the past decade, several phase II/III clinical trials have shown promising results in the use of novel drugs targeting lipid synthase, farnesoid X receptor signaling, peroxisome proliferator-activated receptor signaling, hepatocellular injury, and inflammatory signaling, proven pharmaceutical agents to treat NASH are still lacking. Thus, continuous exploration of the mechanism underlying the pathogenesis of NAFLD and the identification of novel therapeutic targets remain urgent tasks in the field. In the current review, we summarize studies reported in recent years that not only provide new insights into the mechanisms of NAFLD development but also explore the possibility of treating NAFLD by targeting newly identified signaling pathways. We also discuss evidence focusing on the intrahepatic targets involved in the pathogenesis of NAFLD as well as extrahepatic targets affecting liver metabolism and function.

show abstract

“…[ 10 ] Inadequate protein intake is closely related to malnutrition, and albumin (ALB) is an accurate and optimal indicator of the body’s nutritional status. Furthermore, liver and kidney dysfunction, [ 11 , 12 ] metabolic syndrome (elevated blood pressure, fasting hyperglycemia, and lipid levels), [ 13 ] chronic disease(type 2 diabetes, cardiovascular, and pulmonary disease), [ 14 ] and malignancy [ 15 ] have all been reported to be associated with the onset of sarcopenia.…”

Section: Introductionmentioning

confidence: 99%

A nomogram to predict the risk of sarcopenia in older people

et al. 2023

View full text Add to dashboard Cite

The burden of sarcopenia is increasing worldwide. However, most cases of sarcopenia are undiagnosed due to the lack of simple screening tools. This study aimed to develop and validate an individualized and simple nomogram for predicting sarcopenia in older adults. A total of 180 medical examination populations aged ≥60 years were enrolled in this study. Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia 2019 consensus. The primary data were randomly divided into training and validation sets. Univariate logistic regression analysis was performed to select the risk factors of sarcopenia, which were subjected to the least absolute shrinkage and selection operator for feature selection. A nomogram was established using multivariate logistic regression analysis by incorporating the features selected in the least absolute shrinkage and selection operator regression model. The discrimination and calibration of the predictive model were verified by the concordance index, receiver operating characteristic curve, and calibration curve. In this study, 55 cases of sarcopenia were available. Risk predictors included age, albumin, blood urea nitrogen, grip strength, and calf circumference. The model had good discrimination and calibration capabilities. concordance index was 0.92 (95% confidence interval: 0.84–1.00), and the area under the receiver operating characteristic curve was 0.92 (95% confidence interval: 0.83–1.00) in the validation set. The Hosmer-Lemeshow test had a P value of .94. The predictive model in this study will be a clinically useful tool for predicting the risk of sarcopenia, and it will facilitate earlier detection and therapeutic intervention for sarcopenia.

show abstract

Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk

Cited by 21 publications

References 106 publications

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

A nomogram to predict the risk of sarcopenia in older people

Contact Info

Product

Resources

About